Skip to main content

Table 1 Baseline characteristics of the 1003 AS patients and 1747 RA patients who were working at baseline

From: Fatigue independently predicts different work disability dimensions in etanercept-treated rheumatoid arthritis and ankylosing spondylitis patients

Parameter

AS

n

RA

n

Age (years), mean (SD)

40.7 (10.6)

1003

47.3 (9.9)

1747

Female, %

36.7

1003

72.4

1747

Disease duration (years), mean (SD)

7.3 (7.8)

979

7.9 (7.6)

1654

Disease activity

0–10 Likert, mean (SD)

6.3 (1.7)

1000

 

0–100 mm VAS, mean (SD)

 

59.1 (18.0)

1724

CRP (mg/dL), median (min, max)

1.0 (0.0, 42.7)

906

0.9 (0.0, 20.0)

1534

Fatigue

0–10 cm VAS, mean (SD)

5.6 (2.4)

997

 

0–100 mm VAS, mean (SD)

 

57.4 (24.9)

1735

Pain

0–10 Likert, mean (SD)

6.3 (2.2)

990

 

0–100 mm VAS, mean (SD)

 

61.6 (21.4)

1736

Anxiety/depression

(EQ-5D)

No problems, %

53.6

998

52.1

1738

Some problems, %

42.7

44.4

Extreme problems, %

3.7

3.6

WPAI:SHP

% work time missed due to AS/RAa

No timed missed

61.9

776

61.3

1293

Some time missed

38.1

38.7

% impairment while working due to AS/RAb, mean (SD)

48.3 (26.9)

889

49.5 (27.1)

1530

% overall work impairment due to AS/RAc, mean (SD)

52.9 (29.8)

716

54.1 (29.0)

1171

% activity impairment due to AS/RAd, mean (SD)

53.4 (24.6)

990

54.0 (24.9)

1718

  1. aAbsenteeism
  2. bPresenteeism
  3. cWork productivity loss
  4. dActivity impairment
  5. AS, ankylosing spondylitis; CRP, C-reactive protein; EQ-5D, European Quality of Life 5 Dimensions; RA, rheumatoid arthritis; SD, standard deviation; VAS, visual analogue scale; WPAI:SHP, Work Productivity and Activity Impairment—Special Health Problems